HPV

Women older than 40 are unlikely to get much benefit from the vaccine for the virus that causes cervical cancer, a new study reports.

HPV

SAN DIEGO — Inovio Biomedical Corp. announced Feb. 8 additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine trial

HPV

A second vaccine to protect against human papillomavirus, or HPV, has been approved for use in Canada, CBC News reported Feb. 9.

HPV

The number of women under 30 diagnosed with cervical cancer will fall nearly two thirds by 2025 thanks to the vaccine against human papillomavirus, researchers say.

A new study may explain the intense disagreement about proposals to vaccinate elementary-school girls against human papillomavirus, ScienceDaily reported Jan. 14.

HPV

A new study of new couples found that 56 percent of young adults in a new sexual relationship were infected with human papillomavirus, ScienceDaily reported Jan. 14.

Human Papillomavirus

The human papillomavirus (HPV) vaccine Cervarix protects women from infection for longer than six years, new research has found, HealthDay News reported Dec. 2.

Dr. Gemma Kenter

BOSTON — An experimental vaccine cured nearly half of women with pre-cancerous growths on their genitals, producing major improvement in nearly four out of five, researchers in the Netherlands reported in a small study Nov. 4.

Dr. Jane Kim

BOSTON — Persistent infection with high-risk types of human papillomavirus, a sexually transmitted virus, is known to be a cause of cervical cancer.

The U.S. Food and Drug Administration announced Oct. 16 that it approved the use of the vaccine Gardasil to prevent genital warts caused by the human papillomavirus types 6 and 11 in males ages 9 to 26.